Skip to main
ABVX
ABVX logo

Abivax SA (ABVX) Stock Forecast & Price Target

Abivax SA (ABVX) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 30%
Buy 70%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Abivax SA is poised for a positive outlook due to the promising results from its Phase 3 clinical trials of obefazimod, which demonstrated significant efficacy and improved safety/tolerability in treating moderately to severely active ulcerative colitis. The company has raised its peak sales estimates and penetration rates, reflecting increased confidence in obefazimod’s multi-billion-dollar commercial potential in a market characterized by high unmet needs. Furthermore, the drug's rapid therapeutic effect in patients with previous treatment failures enhances its appeal, positioning Abivax favorably within the biotechnology sector.

Bears say

Abivax SA's stock outlook is negatively impacted by the inability to demonstrate compelling maintenance efficacy for its drug candidate, obefazimod, following promising initial induction results, mirroring the setbacks encountered by other therapies in the same space. Furthermore, the company's history of ongoing financial losses and lack of profitability compounds concerns about its commercial viability, especially given the precedent of prior oral therapies that have failed due to efficacy and safety issues. Additionally, uncertainties regarding the company's ability to secure favorable partnerships for commercial launch further exacerbate the risks associated with its clinical positioning within the competitive market for ulcerative colitis treatments.

Abivax SA (ABVX) has been analyzed by 10 analysts, with a consensus rating of Buy. 30% of analysts recommend a Strong Buy, 70% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abivax SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abivax SA (ABVX) Forecast

Analysts have given Abivax SA (ABVX) a Buy based on their latest research and market trends.

According to 10 analysts, Abivax SA (ABVX) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $118.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $118.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abivax SA (ABVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.